nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiotropium—Aneurysm—Fludarabine—lymphatic system cancer	0.0867	0.0867	CcSEcCtD
Tiotropium—Herpes zoster—Mechlorethamine—lymphatic system cancer	0.0258	0.0258	CcSEcCtD
Tiotropium—Skin ulcer—Mechlorethamine—lymphatic system cancer	0.0249	0.0249	CcSEcCtD
Tiotropium—Skin infection—Mitoxantrone—lymphatic system cancer	0.0248	0.0248	CcSEcCtD
Tiotropium—Supraventricular tachycardia—Fludarabine—lymphatic system cancer	0.0192	0.0192	CcSEcCtD
Tiotropium—Ileus paralytic—Vincristine—lymphatic system cancer	0.0178	0.0178	CcSEcCtD
Tiotropium—Herpes zoster—Fludarabine—lymphatic system cancer	0.0167	0.0167	CcSEcCtD
Tiotropium—Oral candidiasis—Carmustine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Tiotropium—Intestinal obstruction—Vincristine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Tiotropium—Dehydration—Fludarabine—lymphatic system cancer	0.00849	0.00849	CcSEcCtD
Tiotropium—Ulcerative stomatitis—Methotrexate—lymphatic system cancer	0.00808	0.00808	CcSEcCtD
Tiotropium—Bone pain—Vincristine—lymphatic system cancer	0.00802	0.00802	CcSEcCtD
Tiotropium—Dysphagia—Fludarabine—lymphatic system cancer	0.00789	0.00789	CcSEcCtD
Tiotropium—Bone pain—Mitoxantrone—lymphatic system cancer	0.00781	0.00781	CcSEcCtD
Tiotropium—Stomatitis—Teniposide—lymphatic system cancer	0.00781	0.00781	CcSEcCtD
Tiotropium—Angina pectoris—Fludarabine—lymphatic system cancer	0.00769	0.00769	CcSEcCtD
Tiotropium—Candida infection—Carmustine—lymphatic system cancer	0.00769	0.00769	CcSEcCtD
Tiotropium—Dysuria—Fludarabine—lymphatic system cancer	0.00738	0.00738	CcSEcCtD
Tiotropium—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00734	0.00734	CcSEcCtD
Tiotropium—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00718	0.00718	CcSEcCtD
Tiotropium—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00712	0.00712	CcSEcCtD
Tiotropium—Mouth ulceration—Vincristine—lymphatic system cancer	0.00695	0.00695	CcSEcCtD
Tiotropium—Renal failure—Fludarabine—lymphatic system cancer	0.00692	0.00692	CcSEcCtD
Tiotropium—Arthritis—Bleomycin—lymphatic system cancer	0.00689	0.00689	CcSEcCtD
Tiotropium—Infection—Mechlorethamine—lymphatic system cancer	0.00688	0.00688	CcSEcCtD
Tiotropium—Stomatitis—Fludarabine—lymphatic system cancer	0.00686	0.00686	CcSEcCtD
Tiotropium—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00684	0.00684	CcSEcCtD
Tiotropium—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00673	0.00673	CcSEcCtD
Tiotropium—Epistaxis—Fludarabine—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Tiotropium—Sinusitis—Fludarabine—lymphatic system cancer	0.0066	0.0066	CcSEcCtD
Tiotropium—Arrhythmia—Teniposide—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Tiotropium—Pharyngitis—Fludarabine—lymphatic system cancer	0.00627	0.00627	CcSEcCtD
Tiotropium—Visual impairment—Fludarabine—lymphatic system cancer	0.00609	0.00609	CcSEcCtD
Tiotropium—Arrhythmia—Fludarabine—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Tiotropium—Pain in extremity—Vincristine—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Tiotropium—Malnutrition—Fludarabine—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Tiotropium—Hypertension—Teniposide—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Tiotropium—Chest pain—Teniposide—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Tiotropium—Urinary retention—Vincristine—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Tiotropium—Dehydration—Vincristine—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Tiotropium—Oedema—Teniposide—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Tiotropium—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Tiotropium—Infection—Teniposide—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Tiotropium—Dehydration—Mitoxantrone—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Tiotropium—Dysphagia—Carmustine—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Tiotropium—Stomatitis—Bleomycin—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Tiotropium—Tachycardia—Teniposide—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Tiotropium—Herpes zoster—Methotrexate—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Tiotropium—Pruritus—Mechlorethamine—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Tiotropium—Cough—Fludarabine—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Tiotropium—Skin ulcer—Methotrexate—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Tiotropium—Gingivitis—Methotrexate—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Tiotropium—Arthralgia—Fludarabine—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Tiotropium—Myalgia—Fludarabine—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Tiotropium—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Tiotropium—Dysuria—Vincristine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Tiotropium—Oedema—Fludarabine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Tiotropium—Infection—Fludarabine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Tiotropium—Renal failure—Carmustine—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Tiotropium—Vomiting—Mechlorethamine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Tiotropium—Nervous system disorder—Fludarabine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Tiotropium—Stomatitis—Carmustine—lymphatic system cancer	0.00439	0.00439	CcSEcCtD
Tiotropium—Urinary tract infection—Carmustine—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Tiotropium—Rash—Mechlorethamine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Tiotropium—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Tiotropium—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Tiotropium—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Tiotropium—Stomatitis—Vincristine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Tiotropium—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Tiotropium—Renal failure—Mitoxantrone—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Tiotropium—Nausea—Mechlorethamine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Tiotropium—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Tiotropium—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Tiotropium—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Tiotropium—Urticaria—Teniposide—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Tiotropium—Glossitis—Methotrexate—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Tiotropium—Abdominal pain—Teniposide—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Tiotropium—Paraesthesia—Fludarabine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Tiotropium—Oedema peripheral—Carmustine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Tiotropium—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Tiotropium—Dyspepsia—Fludarabine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Tiotropium—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Tiotropium—Visual impairment—Carmustine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Tiotropium—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Tiotropium—Constipation—Fludarabine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Tiotropium—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Tiotropium—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Tiotropium—Urethral disorder—Vincristine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Tiotropium—Eye disorder—Carmustine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Tiotropium—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Tiotropium—Hypersensitivity—Teniposide—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Tiotropium—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Tiotropium—Pruritus—Teniposide—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Tiotropium—Arrhythmia—Carmustine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Tiotropium—Mental disorder—Carmustine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Tiotropium—Malnutrition—Carmustine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Tiotropium—Cough—Bleomycin—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Tiotropium—Angiopathy—Vincristine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Tiotropium—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Tiotropium—Myalgia—Bleomycin—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Tiotropium—Chest pain—Bleomycin—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Tiotropium—Back pain—Carmustine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Tiotropium—Mental disorder—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Tiotropium—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Tiotropium—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Tiotropium—Vision blurred—Carmustine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Tiotropium—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Tiotropium—Oedema—Bleomycin—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Tiotropium—Infection—Bleomycin—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Tiotropium—Back pain—Vincristine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Tiotropium—Vomiting—Teniposide—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Tiotropium—Rash—Teniposide—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Tiotropium—Dermatitis—Teniposide—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Tiotropium—Headache—Teniposide—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Tiotropium—Pruritus—Fludarabine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Tiotropium—Back pain—Mitoxantrone—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Tiotropium—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Tiotropium—Hypertension—Carmustine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Tiotropium—Nausea—Teniposide—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Tiotropium—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.003	0.003	CcSEcCtD
Tiotropium—Chest pain—Carmustine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Tiotropium—Myalgia—Carmustine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Tiotropium—Paraesthesia—Bleomycin—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Tiotropium—Hypertension—Vincristine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Tiotropium—Oedema—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Tiotropium—Myalgia—Vincristine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Tiotropium—Cough—Mitoxantrone—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Tiotropium—Infection—Carmustine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Tiotropium—Vomiting—Fludarabine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Tiotropium—Rash—Fludarabine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Tiotropium—Dermatitis—Fludarabine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Tiotropium—Hypertension—Mitoxantrone—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Tiotropium—Headache—Fludarabine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Tiotropium—Tachycardia—Carmustine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Tiotropium—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Tiotropium—Myalgia—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Tiotropium—Chest pain—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Tiotropium—Oedema—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Tiotropium—Infection—Vincristine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Tiotropium—Nervous system disorder—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Tiotropium—Oedema—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Tiotropium—Nausea—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Tiotropium—Infection—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Tiotropium—Shock—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Tiotropium—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Tiotropium—Urticaria—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Tiotropium—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Tiotropium—Insomnia—Carmustine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Tiotropium—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Tiotropium—Paraesthesia—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Tiotropium—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Tiotropium—Insomnia—Vincristine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Tiotropium—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Tiotropium—Paraesthesia—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Tiotropium—Constipation—Carmustine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Tiotropium—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Tiotropium—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Tiotropium—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Tiotropium—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Tiotropium—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Tiotropium—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Tiotropium—Constipation—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Tiotropium—Pruritus—Bleomycin—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Tiotropium—Constipation—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Tiotropium—Abdominal pain—Carmustine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Tiotropium—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Tiotropium—Dysuria—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Tiotropium—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Tiotropium—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Tiotropium—Abdominal pain—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Tiotropium—Urticaria—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Tiotropium—Hypersensitivity—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Tiotropium—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Tiotropium—Vomiting—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Tiotropium—Rash—Bleomycin—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Tiotropium—Dermatitis—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Tiotropium—Renal failure—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Tiotropium—Stomatitis—Methotrexate—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Tiotropium—Hypersensitivity—Vincristine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Tiotropium—Epistaxis—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Tiotropium—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Tiotropium—Nausea—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Tiotropium—Dizziness—Carmustine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Tiotropium—Pharyngitis—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Tiotropium—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Tiotropium—Urethral disorder—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Tiotropium—Vomiting—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Tiotropium—Dizziness—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Tiotropium—Rash—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Tiotropium—Dermatitis—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Tiotropium—Visual impairment—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Tiotropium—Headache—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Tiotropium—Eye disorder—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Tiotropium—Vomiting—Vincristine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Tiotropium—Rash—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Tiotropium—Dermatitis—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Tiotropium—Headache—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Tiotropium—Nausea—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Tiotropium—Angiopathy—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Tiotropium—Vomiting—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Tiotropium—Immune system disorder—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Tiotropium—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Tiotropium—Rash—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Tiotropium—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Tiotropium—Headache—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Tiotropium—Mental disorder—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Tiotropium—Malnutrition—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Tiotropium—Nausea—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Tiotropium—Nausea—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Tiotropium—Back pain—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Tiotropium—Vision blurred—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Tiotropium—Cough—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Tiotropium—Arthralgia—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Tiotropium—Chest pain—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Tiotropium—Myalgia—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Tiotropium—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Tiotropium—Infection—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Tiotropium—Nervous system disorder—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Tiotropium—Skin disorder—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Tiotropium—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Tiotropium—Insomnia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Tiotropium—Paraesthesia—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Tiotropium—Dyspepsia—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Tiotropium—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Tiotropium—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Tiotropium—Urticaria—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Tiotropium—Abdominal pain—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Tiotropium—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Tiotropium—Pruritus—Methotrexate—lymphatic system cancer	0.000941	0.000941	CcSEcCtD
Tiotropium—Dizziness—Methotrexate—lymphatic system cancer	0.00088	0.00088	CcSEcCtD
Tiotropium—Vomiting—Methotrexate—lymphatic system cancer	0.000846	0.000846	CcSEcCtD
Tiotropium—Rash—Methotrexate—lymphatic system cancer	0.000839	0.000839	CcSEcCtD
Tiotropium—Dermatitis—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Tiotropium—Headache—Methotrexate—lymphatic system cancer	0.000834	0.000834	CcSEcCtD
Tiotropium—Nausea—Methotrexate—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
